New COVID-19 drug from ACCORD trial boosts hospital patients’ recovery
A sub-study of the ACCORD trial, led by the Faculty’s Professor Tom Wilkinson, has shown the drug bemcentinib could help to further improve the care COVID-19 patients receive in hospital.
Patients join the ACCORD trial within a day after they are admitted to hospital. Eligible patients are categorized by a 9-point clinical scale system developed by the World Health Organization (WHO).
In the study, 26 of the 29 patients (90 percent) treated with bemcentinib recovered to the extent that they improved by two points on the WHO scoring system or were discharged from hospital. They took an average of seven days to reach this point.
By comparison, 22 of 32 patients (69 percent) on standard care alone reached this point in their recovery, taking an average of nine and a half days.
Related Staff Member
Professor Tom Wilkinson MA Cantab, MBBS, PhD, FRCP
Professor Tom Wilkinson is Professor of Respiratory Medicine and Honorary NHS Consultant Physician within Medicine at the University of Southampton.
Read more